Ani Pharmaceuticals (ANIP) Total Debt (2012 - 2026)

Ani Pharmaceuticals has disclosed Total Debt across 12 years of filings, most recently posting $305.3 million for Q1 2026.

• Total Debt for Q1 2026 came in at $305.3 million, changed 0.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $305.3 million (changed 0.07% YoY), and the FY2025 annual result was $309.1 million, down 2.88% from the prior year.
• Total Debt came in at $305.3 million for Q1 2026 at Ani Pharmaceuticals, down from $309.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $318.3 million in Q4 2024 to a low of $285.0 million in Q1 2024.
• The 5-year median for Total Debt is $305.3 million (2026), against an average of $299.3 million.
• Across the five-year window, Total Debt surged 56.55% in 2022 and decreased 8.07% in 2024, its largest moves.
• Ani Pharmaceuticals' Total Debt stood at $286.5 million in 2022, then retreated by 0.3% to $285.7 million in 2023, then climbed by 11.42% to $318.3 million in 2024, then declined by 2.88% to $309.1 million in 2025, then fell by 1.23% to $305.3 million in 2026.
• The last three Total Debt figures came in at $305.3 million (Q1 2026), $309.1 million (Q4 2025), and $312.9 million (Q3 2025), per Business Quant data.